Pharma R&D Today

The nature of evidence in aging research

Posted on June 5th, 2017 by Dr Andrew A. Parsons in Pharma R&D

It seems a while since there was focus on aging as a suitable target for pharmaceutical intervention. The days of Sirtuins and red wine may be long gone, but the scope of the opportunity to support healthy aging is becoming more relevant. It was therefore with some interest that I noticed several recent articles in FierceBiotech.

Continue reading “The nature of evidence in aging research” »

2016 US Elections Fearful or Fertile Ground for Pharma?

Posted on November 10th, 2016 by Dr. Makarand Jawadekar, Ph.D in Pharma R&D

The elections outcome, the morning after, which is so fresh in everyone’s mind that we need to see how a Trump Presidency will shape the future growth of the US economy and in turn ultimately allow growth in innovation in Pharma Industry. Continue reading “2016 US Elections Fearful or Fertile Ground for Pharma?” »